{'fraction_non_alphanumeric': 0.021568627450980392, 'fraction_numerical': 0.0, 'mean_word_length': 5.2317073170731705, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Asthma and associated drugs

Reactive airways disease, once thought to be a disease of the bronchial smooth muscle, is now recognized as primarily an inflammatory disease. Treatment of the process should be directed at control of inflammation. Current anti-inflammatory treatment relies heavily on corticosteroids, but experimental drugs are focused on interventions that will limit the role of leukotrienes (LTs). Beta-agonists continue to play a role in acute therapy but a declining role in chronic therapy.